SALT LAKE CITY, July 09, 2024 Clene Inc.(Nasdaq: CLNN), a clinical-stage biopharmaceutical company specializing in improving mitochondrial health and protecting neuronal function for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), has revealed plans for a 1-for-20 reverse stock split.The split will take effect at 12:01 a.m.Eastern Time on July 11, 2024.Starting from the opening of trading on that day, Clene’s common stock will be traded on the Nasdaq Capital Market under a new CUSIP number 185634201, while retaining the existing trading symbol CLNN.The CUSIP number for the company’s publicly traded warrants will remain unchanged.
With 128.427231 million shares outstanding, and the current stock price at $0.3473, Clene’s decision to implement a reverse stock split brings some important implications.A reverse stock split consolidates the existing shares of a company, reducing the total number and increasing the price proportionally.In this case, for every 20 shares owned, investors will receive one share at a higher value.
Reverse stock splits are often employed by companies to address low stock prices and to potentially attract institutional investors who may have minimum price requirements for the stocks they purchase.By increasing the stock price, Clene aims to enhance its appeal to a wider range of potential investors, promoting liquidity and aligning with market expectations.
Clene’s focus on improving mitochondrial health and protecting neuronal function is crucial in combating neurodegenerative diseases like ALS and MS.Through innovative approaches and clinical trials, the company aims to develop effective treatments that address the underlying causes of these conditions, providing hope for patients and their families.
The decision to proceed with a reverse stock split highlights Clene’s commitment to strengthen its position in the market, attract more investors, and fund further research and development.As the company continues its pursuit of innovative solutions for neurodegenerative diseases, investors and stakeholders eagerly anticipate the results of their clinical trials and the positive impact it may have on patients’ lives.
Comments